Report library

RVT-101

RVT-101 is a once-daily oral 5-HT6 receptor antagonist being developed by Axovant Sciences for the
treatment of mild to moderate Alzheimer’s disease. The 5-HT6 receptor is found exclusively in the
central nervous system and predominates in regions of the brain associated with cognition and
behavior (Woolley et al., 2004).

September 2, 2016

Uptravi

Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.

October 29, 2018

Disease Analysis: COVID-19 Treatment

COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of 12 March 2021, there have been 117,799,584 confirmed cases of COVID-19, and 2,615,018 confirmed deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus. SARS-CoV-2 is believed to have originated from a horseshoe bat coronavirus, which either spread to humans directly or jumped via an intermediate host (possibly a pangolin), which may have facilitated transmission to humans.

November 1, 2021

Ultibro

Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for

chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU

markets boost its overall clinical and commercial attractiveness.

April 11, 2016

Respiratory Care: Mechanical Ventilators and Pulmonary Function Testing Systems

Asthma and COPD affect an estimated 590 million people worldwide, with an additional 114 million affected by COVID-19 from March 2020 to March 2021. Devices used in the diagnosis and treatment of these and other respiratory disorders include mechanical ventilators and pulmonary function testing systems.

March 30, 2021

Potiga

The novelty and clinical efficacy of Potiga (ezogabine; GlaxoSmithKline) are its greatest strengths. Its

novel mechanism of action on potassium channels is a key clinical differentiator in the competitive

epilepsy market.

July 6, 2016

Market Spotlight: Myelofibrosis

This Market Spotlight report covers the Myelofibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

January 10, 2020

Market Spotlight: Polycystic Ovary Syndrome (PCOS)

This Market Spotlight report covers the Polycystic Ovary Syndrome (PCOS) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

August 24, 2022

International Markets for Vascular Access Site Closure Devices — June 2016

Cardiovascular diseases (CVDs) are the leading causes of death throughout the world. Based on Datamonitor Healthcare estimates, approximately 500 million CVD-related cases occurred in the United States (U.S.), China, Japan, and the five major countries of Europe (France, Germany, Italy, Spain, and the United Kingdom [U.K.]).

June 27, 2016

Zafatek

Zafatek (trelagliptin; Takeda) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.

November 7, 2017

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include the CAR-T therapy Breyanzi, reversible BTK inhibitors MK-1026 and pirtobrutinib, and the PI3K inhibitor TG-1303.

October 1, 2020

CRO League Tables: Acquisition, Competition, and Privatization

$5,000.00

Over the past 12 months, the clinical research outsourcing (CRO) industry has taken its next decisive steps in the evolution of a business making its mark in drug development.

November 3, 2016

Spinal Fusion Implanted Instrumentation Market

This medical market and technology report provides a comprehensive discussion of implanted instrumentation for spinal fusion.

February 28, 2018

Darzalex

Darzalex (daratumumab; Johnson & Johnson) is a human monoclonal antibody against the cluster of differentiation (CD)38 antigen, which is produced in a mammalian cell line…

August 9, 2018

Mircera

Mircera is an ESA administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in CKD

January 11, 2018

Trelegy Ellipta

Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy.

July 31, 2018

Lantus

Lantus (insulin glargine; Sanofi) was the first long-acting basal insulin analog to reach the market.

November 7, 2017

Diabetes Management: Insulin Pumps Market (2022)

In 2021, global sales of insulin pumps and related items were estimated at nearly $3.5bn. Market drivers include technological advancements such as the development of easy to wear pod-based designs and predictive software, the expanding use of insulin pumps as an alternative to syringe-based insulin delivery, an ever-increasing population of individuals requiring insulin drug delivery, and a significant disposables aftermarket. Market limiters include restrained healthcare spending in some countries due to slowed economic growth combined with a high per unit cost for insulin pumps. Additionally, supply chain disruptions as a result of the Russian invasion of Ukraine, and a shortage of shipping containers have constrained growth. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for automated insulin pumps and related accessories. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021–26.

August 25, 2022

Non-Small Cell Lung Cancer KOL Interview

Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

December 16, 2016

Alpelisib

Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.

February 5, 2016

Drug Pricing and Market Access KOL Interview

Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.

February 1, 2016

2016 Post-AHA Report

$5,000.00

The American Heart Association (AHA) Scientific Sessions 2016 was held in New Orleans, LA from November 12-16. The most interesting results were from PCSK9 inhibitors, with details from Repatha’s positive atherosclerosis imaging study and Phase II data.

December 12, 2016

U.S. Markets for Heart Valve Disorder Management Products

This comprehensive report examines the etiology and epidemiology, number of hospital discharges, incidence and prevalence, and mortality rates of the most prevalent diseases/disorders in the United States for the years 2000-2010, and 2013.

September 22, 2016

Flucelvax QIV

Flucelvax is an inactivated subunit cell-based QIV that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

January 10, 2019

Orthobiologics Market for Musculoskeletal Soft Tissue Replacement and Regeneration

This report provides an analysis and sales forecast for the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration. Market segments covered in this report include:

July 20, 2017

Prostate Cancer KOL Interview – UK #2

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

February 9, 2022

Market Spotlight: Tuberculosis (TB)

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals.

July 20, 2022

Coumadin

Coumadin is an orally available vitamin K antagonist (VKA) indicated for the prophylaxis and

treatment of deep vein thrombosis and pulmonary embolism.

August 2, 2016

IMO-2125

IMO-2125 is a synthetic phosphorothioate oligonucleotide-based agonist of toll-like receptor 9 (TLR9) designed to mimic the bacterial DNA that normally activates TLR9.

May 23, 2018

Type 1 Diabetes KOL Interview – US, Midwest

This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.

January 8, 2020

2018 Biomedtracker Datamonitor Healthcare Post-ASH Report

The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018.

January 3, 2019

GSK-3003891A

GSK-3003891A (GlaxoSmithKline) is an alum-adjuvanted respiratory syncytial virus (RSV) vaccine based on the prefusion form of the RSV fusion (F) protein. It is currently in Phase II development in the US and EU.

October 5, 2018

Diabetes Management: Blood Glucose Monitoring Devices Market

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

December 19, 2019

Vasotec

Vasotec’s (enalapril; Merck & Co/Valeant) role in chronic heart failure (CHF) is severely limited by

competition from generic equivalents.

August 2, 2016

Market Spotlight: Primary Sclerosing Cholangitis (PSC)

This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) market, comprising key pipeline drugs and upcoming events, clinical trials, probability of success, and a 10-year disease prevalence forecast.

August 17, 2022

Breast Cancer Pulse #2

We performed a 5-question survey of 24 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs and drug candidates discussed: •Neratinib, PBYI •Herceptin (trastuzumab), Roche •Perjeta (pertuzumab), Roche •Kadcyla (trastuzumab-DM1), Roche •Tykerb (lapatinib), GSK

October 31, 2016

First-In-Class Therapies’ Shrinking In-Class Monopolies

$2,995.00

Competition from drugs in the same class (with the same mechanism of action and treating the same disease) presents a clear challenge to a first-in-class market entrant. And the speed with which these competitors arrive impacts market dynamics, commercial strategies, and, increasingly, drug prices. Therapies that enjoy extended monopolies as sole entrants in a particular class have greater commercial flexibility in negotiating with payers. Multiple drugs in the same class give payers better leverage with which to negotiate rebates and discounts with drug companies.

November 15, 2018

UK Regulatory Issues

$2,995.00

Recently there have been several new regulatory changes in the UK aimed at reducing the regulatory burden and allowing earlier access to medicines which are seen as a positive development for the pharmaceutical industry.

November 2, 2016

VK2809

VK2809 (Viking Therapeutics) is a thyroid hormone receptor (THR) β-selective agonist which is selective to liver tissue. It is delivered as a prodrug. VK2809 selectively activates the cytochrome P450 isozyme 3A4 (CYP3A4), which is predominantly found in the liver. This allows increased hepatic exposure, which simultaneously reduces systemic exposure to other tissues such as skeletal muscle and the heart.

July 22, 2019

Contract Research Organizations: Health and Wealth in 2013

$5,000.00

For public contract research organizations (CROs), the financial story in 2013 was one of solid and steady growth. Revenues grew and company-estimated forecasts for 2014 are also positive.

November 3, 2016

Market Spotlight: Sickle Cell Anemia

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.

June 9, 2022

Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.

February 4, 2019

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.

April 21, 2022

Siponimod

Siponimod (Novartis) is a sphingosine-1-phosphate (S1P) agonist with selectivity for the S1P1 and S1P5 receptor subtypes.

November 24, 2017